Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR1 | P32241 | 3/20 | 0.42 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.41 |
| ▸ | NPY4R | P50391 | 5/20 | 0.41 |
| ▸ | NPY1R | P25929 | 4/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16313964 | 1.00 | VIPR1 (0.42) | VIPR1VIPR2NPY5RNPY4RNPY1R | |
| SCHEMBL16357955 | 0.93 | KISS1R (0.43) | VIPR1VIPR2NPY5RNPY4RNPY1R | |
| SCHEMBL13723928 | 0.93 | KISS1R (0.43) | VIPR1VIPR2NPY5RNPY4RNPY1R | |
| SCHEMBL13220270 | 0.92 | OPRM1 (0.41) | VIPR1VIPR2NPY5RNPY4RNPY1R | |
| SCHEMBL13723684 | 0.91 | RXFP1 (0.43) | VIPR1VIPR2 | |
| SCHEMBL13723715 | 0.89 | RXFP1 (0.42) | NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL13723936 | 0.89 | RXFP1 (0.43) | VIPR1VIPR2NPY5RNPY4RNPY1R | |
| SCHEMBL13723416 | 0.89 | VIPR1 (0.39) | VIPR1VIPR2NPY5RNPY4RNPY1R | |
| SCHEMBL13723019 | 0.88 | RXFP1 (0.42) | VIPR1VIPR2 | |
| SCHEMBL13723138 | 0.88 | RXFP1 (0.42) | VIPR1VIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
| WO-2007118691-A1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | VIPR1 1436/4885VIPR2 1533/4885NPY5R 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.